Skip to main
SLDB
SLDB logo

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 58%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences Inc. exhibits a positive outlook due to its focused approach in developing gene therapies for Duchenne muscular dystrophy (DMD), demonstrated by significant mean improvements in the North Star Ambulatory Assessment (NSAA) among treated patients. The company's innovative treatment, del-zota, has shown a dose-dependent increase in dystrophin expression and clinically meaningful functional improvements across various endpoints, indicating strong therapeutic potential. Furthermore, advancements in antibody-oligonucleotide conjugates and their associated benefits, such as enhanced efficacy and convenience over traditional therapies, suggest solid growth prospects within the competitive landscape of neuromuscular disease treatments.

Bears say

The analysis indicates a negative outlook for Solid Biosciences Inc, primarily due to disappointing clinical data, including a decline in NSAA scores and a significant reduction in dystrophin expression levels. The company's projections face considerable risks stemming from potential safety issues and regulatory challenges that may hinder the approval of their key therapy, SGT-003. Furthermore, results from larger studies suggest lower efficacy compared to earlier trials, amplifying concerns about the company's future financial performance and the viability of their product pipeline.

Solid Biosciences (SLDB) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 58% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 12 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.